Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Bevacizumab Ranibizumab

Research Leaders

5 sponsors active, led by Universidad Autonoma de San Luis Potosí

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 3 (1)
Phase 4 (2)

Trial Status

Recruiting1
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06520410Phase 4RecruitingPrimary

Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries

NCT05033106Phase 3UnknownPrimary

Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity

NCT03148132Phase 4CompletedPrimary

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

Showing all 3 trials

Research Network

Common Treatments

  • Bevacizumab Ranibizumab1
  • Bevacizumab1
  • Ranibizumab1
  • Pars Plana Vitrectomy With A 18 Mm Short Vitrector1

Active Sponsors

  • Universidad Autonoma de San Luis Potosí1
  • Cairo University1
  • Hospital Central "Dr. Ignacio Morones Prieto"1
  • Chang Gung Memorial Hospital1
  • Zagazig University1

Top Investigators

Related Conditions

  • Retinal Disease2
  • Vitreous Anomalies1
  • Familial Exudative Vitreoretinopathies1
  • Premature Birth1
  • Coats Disease1

Activity Timeline